Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Juntaro
J
Matsuzaki
Hidekazu
H
Suzuki
Toshihiro
T
Nishizawa
Kenro
K
Hirata
Hitoshi
H
Tsugawa
Yoshimasa
Y
Saito
Sawako
S
Okada
Seiichiro
S
Fukuhara
Toshifumi
T
Hibi
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000235:genetics*; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D027081:DNA Gyrase / Q000235:genetics*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009154:Mutation; D017211:Treatment Failure
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D054316:Biomarkers, Pharmacological; D024841:Fluoroquinolones; D008795:Metronidazole; C076246:sitafloxacin; D027081:DNA Gyrase; D017291:Clarithromycin